Monday, 11 April 2016

Sun Pharma shares up 2% intraday on USFDA nod for BromSite

The company may commercialise BromSite through its new US division Sun Opthalmics later in the year. Sun Pharma stock price rose by nearly 2% on Monday after the company received an approval from the US health regulator USFDA for its non-steroid ... Read More

No comments:

Post a Comment